SOCIETAL IMPACT OF DIABETIC MACULAR EDEMA TREATMENT IN MOROCCO: A DISEASE-LEVEL SOCIAL IMPACT ASSESSMENT USING A HUMAN CAPITAL APPROACH
Author(s)
Omar Maoujoud, PhD, MD1, sanaa haouraji, Msc2.
1Research Team of pharmacoeconomics & pharmacoepidemiology, Faculty of Medicine Mohammed V University, Rabat, Morocco, 2EOS Executive Lab, Casablanca, Morocco.
1Research Team of pharmacoeconomics & pharmacoepidemiology, Faculty of Medicine Mohammed V University, Rabat, Morocco, 2EOS Executive Lab, Casablanca, Morocco.
OBJECTIVES: To quantify the societal burden of diabetic macular edema (DME) in Morocco and the share recoverable by closing the guideline-concordant treatment gap, using a disease-level social impact assessment (SIA).
METHODS: A disease-level SIA was conducted from a societal perspective over 2026-2035 (MAD 2026; 3% symmetric discounting on costs and effects), following a structured societal-impact assessment framework and CHEERS 2022 reporting standards. The Human Capital Approach valued three productivity pillars: paid market work, unpaid domestic work, and informal caregiving (valued at replacement cost). A Type II input-output multiplier (1.80) was applied to paid and unpaid productivity to capture indirect economy-wide effects. The epidemiological cascade combined national adult diabetes prevalence with published diabetic-retinopathy and DME ratios. Incremental societal impact (SI) reflected treatment-gap closure under a realistic access scenario versus current standard of care. Deterministic and probabilistic (Latin hypercube, N=5000) sensitivity analyses were performed.
RESULTS: An estimated 191,440 prevalent DME cases were identified, of whom 81% (155,259 patients) remained untreated, corresponding to 17,720 disability-adjusted life-years (GBD 2019). The cumulative discounted societal burden of DME reached MAD 44.1 billion. Closing the treatment gap generated an incremental discounted SI of MAD 11.35 billion, recovering 25.7% of the societal burden over ten years, consistent with published societal-impact benchmarks (25-40%). Unpaid domestic productivity was the dominant pillar (68% of SI), followed by informal caregiving (19%) and paid productivity (13%). Sensitivity analyses supported the robustness of the base-case estimate, with health-state utility and domestic-work valuation among the most influential parameters.
CONCLUSIONS: DME imposes a substantial societal burden in Morocco, and expanding treatment access recovers approximately one quarter of it within a decade. This disease-level SIA quantifies value beyond the payer perspective and supports prioritizing diabetic eye care in national health investment, with a framework transferable to other chronic conditions in low- and middle-income settings.
METHODS: A disease-level SIA was conducted from a societal perspective over 2026-2035 (MAD 2026; 3% symmetric discounting on costs and effects), following a structured societal-impact assessment framework and CHEERS 2022 reporting standards. The Human Capital Approach valued three productivity pillars: paid market work, unpaid domestic work, and informal caregiving (valued at replacement cost). A Type II input-output multiplier (1.80) was applied to paid and unpaid productivity to capture indirect economy-wide effects. The epidemiological cascade combined national adult diabetes prevalence with published diabetic-retinopathy and DME ratios. Incremental societal impact (SI) reflected treatment-gap closure under a realistic access scenario versus current standard of care. Deterministic and probabilistic (Latin hypercube, N=5000) sensitivity analyses were performed.
RESULTS: An estimated 191,440 prevalent DME cases were identified, of whom 81% (155,259 patients) remained untreated, corresponding to 17,720 disability-adjusted life-years (GBD 2019). The cumulative discounted societal burden of DME reached MAD 44.1 billion. Closing the treatment gap generated an incremental discounted SI of MAD 11.35 billion, recovering 25.7% of the societal burden over ten years, consistent with published societal-impact benchmarks (25-40%). Unpaid domestic productivity was the dominant pillar (68% of SI), followed by informal caregiving (19%) and paid productivity (13%). Sensitivity analyses supported the robustness of the base-case estimate, with health-state utility and domestic-work valuation among the most influential parameters.
CONCLUSIONS: DME imposes a substantial societal burden in Morocco, and expanding treatment access recovers approximately one quarter of it within a decade. This disease-level SIA quantifies value beyond the payer perspective and supports prioritizing diabetic eye care in national health investment, with a framework transferable to other chronic conditions in low- and middle-income settings.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE428
Topic
Economic Evaluation, Epidemiology & Public Health, Methodological & Statistical Research
Topic Subcategory
Novel & Social Elements of Value, Thresholds & Opportunity Cost, Value of Information
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Geriatrics, Sensory System Disorders (Ear, Eye, Dental, Skin)